Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACRS | US
0.01
0.86%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.17
1.16
1.18
1.16
Aclaris Therapeutics Inc. operates a clinical-stage biopharmaceutical company develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis and Hidradenitis suppurativa; and ATI-1777 a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138 an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231 an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics Inc. was incorporated in 2012 and is headquartered in Wayne Pennsylvania.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
28.3%1 month
38.0%3 months
38.8%6 months
50.3%-
-
0.63
0.02
0.02
0.28
35.36
-0.13
-82.15M
83.47M
83.47M
-
-457.48
-
48.00
-37.43
6.27
2.89
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.10
Range1M
0.10
Range3M
0.30
Rel. volume
0.75
Price X volume
237.31K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
InflaRx N.V | IFRX | Biotechnology | 1.55 | 91.27M | 2.65% | n/a | 0.00% |
Tiziana Life Sciences PLC | TLSA | Biotechnology | 0.896 | 90.96M | 1.82% | n/a | 0.00% |
CytomX Therapeutics Inc | CTMX | Biotechnology | 1.16 | 90.62M | -1.69% | 7.67 | -37.61% |
Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.05 | 89.59M | -0.49% | n/a | 35.26% |
BioAtla Inc. | BCAB | Biotechnology | 1.85 | 89.42M | -5.61% | n/a | 5.30% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.33 | 89.16M | -2.92% | n/a | 0.73% |
MediciNova Inc | MNOV | Biotechnology | 1.805 | 88.53M | -2.43% | n/a | 0.86% |
Clearside Biomedical Inc | CLSD | Biotechnology | 1.15 | 85.96M | 2.68% | n/a | -168.27% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.43 | 83.95M | 0.56% | n/a | 167.26% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.6 | 83.54M | 0.00% | n/a | 6.06% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.28 | 0.53 | Cheaper |
Ent. to Revenue | 35.36 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.63 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 38.77 | 72.92 | Lower Risk |
Debt to Equity | 0.02 | -1.24 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 83.47M | 3.78B | Emerging |